NCT02280434已完成1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CBP-307 Following Oral Single and Multiple Escalating Dose Administration
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
研究概览
简要总结
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects.
详细描述
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects. The study will have two parts: Part 1 will assess 5 dose levels of the drug in single dosing; and Part 2 will evaluate 3 dose levels in 28-day repeat dosing. The effect of food will also be evaluated in a single dosing study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Informed consent must be obtained in writing for all subjects at enrollment into the study
- •Healthy male subjects age between 18 and 55 years, inclusive
- •Body mass index (BMI) between 19 and 30 kg/m2, inclusive
- •No clinically significant findings in the medical history and physical examination, especially with regard to the liver and gastrointestinal systems
- •No clinically significant laboratory values and urinalysis, unless the investigator considers any abnormality to be clinically irrelevant
- •Normal ECG, blood pressure, and heart rate, unless the investigator considers any abnormality to be clinically irrelevant
- •Resting heart rate ≥ 55 bpm
排除标准
- •Family history of premature CHD (Coronary Heart Disease)
- •Any condition requiring the regular use of any medication
- •Exposure to prescription medications or to drugs known to interfere with metabolism of drugs within 30 days prior to screening
- •Exposure to any other medication, including over-the counter medications, herbal remedies and vitamins 14 days prior to randomization (except paracetamol (see Section 5.2 Prior and concomitant treatments)
- •Participation in another study with any investigational drug in the 2 months preceding the study
- •Treatment in the previous 3 months with any drug known to have a well defined potential for toxicity to a major organ
- •Positive urine cotinine result at screening
- •Be in the exclusion period of any previous study with investigational drugs
- •Symptoms of a clinically significant illness in the 3 months before the study
- •Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
- •Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease
- •Hemorrhoids or anal diseases with regular or recent presence of blood in feces
- •History of significant allergic disease (e.g. medications) and acute phase of allergic rhinitis in the previous 2 weeks before randomization or any food allergy
- •Blood or plasma donation of more than 500 ml during the previous 2 month before randomization and/or more than 50 ml in the 2 weeks prior to screening
- •Subjects at risk for tuberculosis (TB), specifically subjects with: Current clinical, radiographic or laboratory evidence of active TB; history of active TB unless there is documentation that the prior anti-TB treatment was appropriate in duration and type;latent TB which has not been successfully treated; a positive quantiFERON® test at screening or within 6 months prior to Day 1
- •Known positive test for HIV
- •Known positive test for hepatitis B (antigens HBs, antibody HBc) or C, unless caused by immunization
- •History of shingles or recurrent episodes of HSV1 or HSV2 infections
- •Current evidence of drug abuse or history of drug abuse within one year before randomization
- •History of alcohol abuse or active alcoholism as defined in Appendix A Definition of alcohol abuse
- •Mental condition rendering the subject incapable to understand the nature, scope, and possible consequences of the study
- •Adults under guardianship and people with restriction of freedom by administrative or legal decisions
- •Unlikely to comply with the clinical study protocol; e.g. uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study
- •Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
- •Systolic blood pressure less than 95 mmHg or greater than 140 mmHg, or diastolic blood pressure less than or equal to 50 mmHg or greater than or equal to 95 mmHg.
- •Subjects with resting heart rate less than 55 beats per minute or greater than 90 beats per minute.
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive a single dose or once daily dose of matching placebo for 28 days.
干预措施: Placebo (Drug)
CBP-307
Active Comparator
Participants will receive a single dose or once daily dose of CBP-307 for 28 days.
干预措施: CBP-307 (Drug)
结局指标
主要结局
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
时间窗: up to 6 weeks
Safety measurements will include vital signs, hematology, blood chemistry, blood pressure and other readouts.
次要结局
- Plasma Concentrations of Study Drug Over Time and Maximal Plasma Concentration (Cmax)(Up to 6 weeks)
- Elimination Half-live (T1/2) of Study Drug(Up to 6 weeks)
- Exposure to Study Drug Measured as Area Under the Curve (AUC)(Up to 6 weeks)
- Effect of Study Drug on Blood Lymphocyte Counts(Up to 6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy SubjectsAutoimmune DiseasesNCT04818229Connect Biopharma Australia Pty Ltd112
已完成
1 期
Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy AdultsHealthy Adult SubjectsNCT04811469Connect Biopharma Australia Pty Ltd74
已完成
2 期
A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic DermatitisModerate-to-severe Atopic DermatitisNCT04444752Suzhou Connect Biopharmaceuticals, Ltd.226
已完成
2 期
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)Moderate to Severe Ulcerative ColitisNCT04700449Suzhou Connect Biopharmaceuticals, Ltd.145
已完成
2 期
Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an ExacerbationChronic Obstructive Pulmonary DiseaseNCT01332097Mereo BioPharma183